Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Astellas Pharma ( (JP:4503) ) is now available.
Astellas Pharma has announced the continuation of its Performance-linked Stock Compensation Scheme for fiscal year 2025, aimed at incentivizing its directors. This scheme, which employs a Board Incentive Plan (BIP) Trust, aligns executive compensation with the company’s long-term growth and shareholder value, reflecting a strategic focus on enhancing enterprise value.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas Pharma Inc. is a pharmaceutical company based in Tokyo, Japan. It focuses on developing innovative therapies in areas such as oncology, urology, immunology, and neuroscience, aiming to improve the health and well-being of people worldwide.
Average Trading Volume: 6,845,444
Technical Sentiment Signal: Sell
Current Market Cap: Yen2470.6B
Learn more about 4503 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue